Skip to main content

Revenues and Earnings up for ABI in Q3 of FY2004

NEW YORK, April 27 (GenomeWeb News) - Applied Biosystems reported increased revenues and earnings for its fiscal year 2004 third quarter today.


Revenues for the quarter were $439.6 million, up from $409.4 million during the same quarter last year.


Revenues in different product categories were as follows (year-ago revenues in brackets): DNA sequencing $137.5 million ($143.6 million), SDS and other applied genomics $111.6 million ($86.8 million), mass spectrometry $109.4 million ($93.3 million), core DNA synthesis and PCR $50.2 million ($50.7 million), other product lines $30.9 million ($35 million).


R&D spending decreased to $57.1 million, from $60 million during the year-ago period.


ABI's net earnings for the quarter were $46 million, or $.22 per share, up from $40.1 million, or $.19 per share, during the same period last year.


The company, a unit of Applera, did not include its assets in its financial statement.


The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.